Method for treating pervasive development disorders
A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.
1. A method of treating a pervasive development disorder (PDD), comprising:
administering a pharmaceutical composition comprising digestive enzymes to an individual having a PDD and a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise amylase, protease and lipase, and wherein one or more symptoms of the PDD are ameliorated.
2. The method of claim 1 , wherein the PDD is selected from the group consisting of Autism, Asperger's, attention deficit disorder (ADD), and attention deficit hyperactive disorder (ADHD).
3. The method of claim 1 , wherein the individual is from 2 to 4 years of age.
4. The method of claim 1 , wherein the individual is from 1 to 6 years of age.
5. The method of claim 1 , wherein the individual is from 5 to 12 years of age.
6. The method of claim 1 , wherein the individual is from 7 to 12 years of age.
7. The method of claim 1 , wherein the individual is from 2 to 12 years of age.
8. The method of claim 1 , wherein the individual is from 1 to 12 years of age.
9. The method of claim 1 , wherein the pharmaceutical composition is administered from 3-6 times per day.
10. The method of claim 1 , wherein the pharmaceutical composition is administered 3 times per day.
11. The method of claim 1 , wherein a dose of the digestive enzymes comprises from 4,000-20,000 U.S.P. units of lipases.
12. The method of claim 1 , wherein a dose of the digestive enzymes comprises from 10,000-50,000 U.S.P. units of proteases.
13. The method of claim 1 , wherein a dose of the digestive enzymes comprises from 10,000-60,000 U.S.P. units of amylases.
14. The method of claim 1 , wherein a dose of the digestive enzymes comprises from 2,000-6,000 U.S.P. units of pancreatin.
15. The method of claim 1 , wherein the digestive enzymes are provided as pancreatin.
16. The method of claim 1 , wherein the individual's fecal chymotrypsin level is determined by using an enzymatic spectrophotometry method.
17. The method of claim 16 , wherein the enzymatic spectrophotometry method is performed at 30° C.
18. The method of claim 1 , wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm.
19. The method of claim 1 , wherein the individual's determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.
20. The method of claim 1 , wherein the individual's determined fecal chymotrypsin level is below 4.2 U/gm.